Denali Therapeutics director sells $261,928 in stock By Investing.com
Denali Therapeutics director sells $261,928 in stock By Investing.com
- Investing
Ramit Sethi- 3 minutes read
Nancy Thornberry, a director at Denali Therapeutics Inc. (), sold a total of 11,439 shares of common stock on September 2, 2026, for an aggregate value of $261,928. The shares were sold at prices ranging from $22.54 to $23.85 per share.
The transactions were executed under a Rule 10b5-1 trading plan, which was adopted on June 3, 2026. The sales come as DNLI stock trades at $22.28, up 35% year-to-date and 44% over the past year, though still 18% below its 52-week high of $27.30.
Specifically, Thornberry sold 10,824 shares at a weighted average price of $22.85, with individual sale prices between $22.54 and $23.52. An additional 615 shares were sold at a weighted average price of $23.74, with prices ranging from $23.59 to $23.85.
Following these sales, Thornberry directly holds 19,686 shares of Denali Therapeutics common stock. This total includes 6,408 unvested Restricted Stock Units (RSUs).According to InvestingPro analysis, DNLI appears undervalued at current levels, with the company holding more cash than debt on its balance sheet. Investors seeking deeper insights can access the comprehensive Pro Research Report, along with 6 additional ProTips and advanced financial metrics on the platform.
In other recent news, Denali Therapeutics reported a significant revenue miss for the second quarter of 2026. The company announced a revenue of $3.6 million, falling short of Wall Street’s expectations of $11.94 million. Additionally, Denali posted an adjusted loss of $0.68 per share, which was wider than the anticipated loss of $0.64 per share. Despite these financial results, the company’s stock saw an increase in after-hours trading. This development comes as Denali launches AVLAYAH, its first approved medicine, which generated $3.6 million in its initial full commercial quarter following FDA approval. Investors are closely monitoring the early commercial performance of AVLAYAH amid the earnings shortfall.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
